Survival outcomes of testicular cancer (TC) in Hispanic men based on analyses from the National Cancer Database (NCDB).

622 Background: The incidence of TC among Hispanic men has been rising, as reported in our analysis of patients in the United States (Yu et al., JCO 2024 42 (4):503). We sought to determine the survival outcomes in Hispanic men based on data obtained from the National Cancer Database (NCDB). Methods: We extracted patient-level data from the NCDB and identified the incidence, demographics, treatment patterns, and outcomes in Hispanic men with TC diagnoses (non-seminoma, NS; seminoma, S) from 2004 to 2020. Results: There were a total of 89550 patients (pts) in the database. Median age at diagnosis was 37 years and 29 years for S and NS pts, respectively. There were 11005 (12.3%) TC pts designated as Hispanic (H), of whom 5396 and 5609 had S and NS TCs, respectively. In contrast, there were a total number of 74350 non-Hispanic (NH) patients with TC; n = 43629 with S, n = 30721 with NS. The majority of H pts had a Charlson-Deyo score of 0 (94.2%). Less than half of H pts had private insurance (48.8%) compared to three-quarters of NH patients (75.1%). 19.6% of H pts were diagnosed with stage II & III TC (compared to 15.8% in NH pts). Pts were treated at academic/research centers in 6.6% of H pts versus 10.8% in NH pts. For S pts, radiation was utilized in 19.4% of H pts vs 25.8% in NH pts, chemotherapy utilized in 28.3% H pts vs 24.4% in NH pts, whereas chemotherapy for NS pts was utilized in 60.1% in H pts vs 53.4% in NH pts. Overall Survival (OS) was not significantly different in S pts for H pts vs NH pts (Log-rank p = 0.066), but among NS pts, H patients did worse compared to NH pts (Log-rank p < 0.001) although OS differences were seen in pooled analyses of S and NS pts (log-rank p < 0.001). Conclusions: Our analysis reports on the treatment patterns and survival of Hispanic men with TC. Survival appears to be worse for Hispanic patients with non-seminoma compared to non-Hispanic patients, but outcomes for seminoma are similar. We also noted slight differences in patterns of treatment receipt for seminoma versus non-seminoma in Hispanic men which may have to do with stage at diagnosis and access to care.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-02-10
DOI
https://doi.org/10.1200/jco.2025.43.5_suppl.622
Primary Topic
Testicular diseases and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Survival outcomes of testicular cancer (TC) in Hispanic men based on analyses from the National Cancer Database (NCDB).

Jeanny B. Aragon‐Ching, Eun-mi Yu, Hongkun Wang
Journal of Clinical Oncology
Testicular diseases and treatments
article

Survival outcomes of testicular cancer (TC) in Hispanic men based on analyses from the National Cancer Database (NCDB).

Jeanny B. Aragon‐Ching, Eun-mi Yu, Hongkun Wang
article en

Abstract

622 Background: The incidence of TC among Hispanic men has been rising, as reported in our analysis of patients in the United States (Yu et al., JCO 2024 42 (4):503). We sought to determine the survival outcomes in Hispanic men based on data obtained from the National Cancer Database (NCDB). Methods: We extracted patient-level data from the NCDB and identified the incidence, demographics, treatment patterns, and outcomes in Hispanic men with TC diagnoses (non-seminoma, NS; seminoma, S) from 2004 to 2020. Results: There were a total of 89550 patients (pts) in the database. Median age at diagnosis was 37 years and 29 years for S and NS pts, respectively. There were 11005 (12.3%) TC pts designated as Hispanic (H), of whom 5396 and 5609 had S and NS TCs, respectively. In contrast, there were a total number of 74350 non-Hispanic (NH) patients with TC; n = 43629 with S, n = 30721 with NS. The majority of H pts had a Charlson-Deyo score of 0 (94.2%). Less than half of H pts had private insurance (48.8%) compared to three-quarters of NH patients (75.1%). 19.6% of H pts were diagnosed with stage II & III TC (compared to 15.8% in NH pts). Pts were treated at academic/research centers in 6.6% of H pts versus 10.8% in NH pts. For S pts, radiation was utilized in 19.4% of H pts vs 25.8% in NH pts, chemotherapy utilized in 28.3% H pts vs 24.4% in NH pts, whereas chemotherapy for NS pts was utilized in 60.1% in H pts vs 53.4% in NH pts. Overall Survival (OS) was not significantly different in S pts for H pts vs NH pts (Log-rank p = 0.066), but among NS pts, H patients did worse compared to NH pts (Log-rank p < 0.001) although OS differences were seen in pooled analyses of S and NS pts (log-rank p < 0.001). Conclusions: Our analysis reports on the treatment patterns and survival of Hispanic men with TC. Survival appears to be worse for Hispanic patients with non-seminoma compared to non-Hispanic patients, but outcomes for seminoma are similar. We also noted slight differences in patterns of treatment receipt for seminoma versus non-seminoma in Hispanic men which may have to do with stage at diagnosis and access to care.

Journal of Clinical OncologyVol. 43(5_suppl)
Georgetown University (US), Virginia Cancer Institute (US)
Openalex Percentile: Top 95%
Testicular diseases and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.